Nova Leap Health Corp. Announces Execution of Definitive Agreement
Nova Leap Health Corp. Announces Execution of Definitive Agreement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
不用於在美國傳播或分發給美國新聞通訊社
HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) ("Nova Leap" or "the Company"), a growing home health care organization, is pleased to announce that it has executed a definitive agreement (the "Agreement"), dated April 25, 2024, to acquire a home care services company ("the Target") with operations in Massachusetts. The Target reported unaudited annualized 2023 revenues of approximately $800,000 and Adjusted EBITDA of approximately $100,000. All amounts are in United States Dollars ("USD") unless otherwise specified.
新斯科舍省哈利法克斯,2024 年 4 月 26 日(環球新聞專線)— NOVA LEAP HEALTH CORP.多倫多證券交易所股票代碼:NLH)(“Nova Leap” 或 “公司”)是一家成長中的家庭醫療保健組織,欣然宣佈,它已於2024年4月25日簽訂了收購一家在馬薩諸塞州開展業務的家庭護理服務公司(“目標”)的最終協議(“協議”)。塔吉特報告稱,2023年未經審計的年化收入約爲80萬美元,調整後的息稅折舊攤銷前利潤約爲10萬美元。除非另有說明,否則所有金額均以美元(“USD”)爲單位。
Under the terms of the Agreement, the acquisition is to be made for total consideration of $300,000 of which $250,000 is payable with cash on closing and $50,000 is by way of a promissory note repayable over a two-year period.
根據協議條款,此次收購的總對價爲300,000美元,其中25萬美元應在收盤時以現金支付,5萬美元以期票的形式支付,爲期兩年。
The acquisition is expected to be immediately accretive, is at arm's length and there are no finder fees to be paid. Closing of the acquisition is expected to occur within the first two weeks of May.
此次收購預計將立即增加收益,觸手可及,無需支付任何發現費。此次收購預計將在5月的前兩週內完成。
"As mentioned in my March 7 Letter to Shareholders, Nova Leap is in an excellent position to re-engage its acquisition program," said Chris Dobbin, President & CEO of Nova Leap. "We are pleased to execute our first acquisition of 2024 in Massachusetts, a state where we currently operate several agencies and where we see significant potential for growth in the future. We're looking forward to working with a great group of people upon closing of the acquisition."
Nova Leap總裁兼首席執行官克里斯·多賓表示:“正如我在3月7日給股東的信中提到的那樣,Nova Leap處於重新參與其收購計劃的絕佳地位。”“我們很高興在馬薩諸塞州執行2024年的首次收購,我們目前在該州經營多家機構,我們認爲該州未來有巨大的增長潛力。我們期待在收購完成後與一大群人合作。”
About Nova Leap
Nova Leap is an acquisitive home health care services company operating in one of the fastest-growing industries in the U.S. & Canada. The Company performs a vital role within the continuum of care with an individual and family centered focus, particularly those requiring dementia care. Nova Leap achieved the #42 ranking on the 2021 Report on Business ranking of Canada's Top Growing Companies, the #2 ranking on the 2020 Report on Business ranking of Canada's Top Growing Companies and the #10 Ranking in the 2019 TSX Venture 50 in the Clean Technology & Life Sciences sector. The Company is geographically diversified with operations in 10 different U.S. states within the New England, Southeastern, South Central and Midwest regions as well as in Nova Scotia, Canada.
關於 Nova Le
Nova Leap 是一家收購型家庭醫療保健服務公司,業務範圍是美國和加拿大增長最快的行業之一。公司以個人和家庭爲中心,在持續的護理中發揮着至關重要的作用,尤其是那些需要癡呆症護理的患者。Nova Leap在《2021年加拿大最佳成長型公司商業報告》排名中排名第 #42 位,在《2020年加拿大最佳成長型公司商業報告》排名中排名第 #2 位,在清潔技術和生命科學領域的2019年多倫多證券交易所風險投資50強中排名第 #10 位。該公司的地域多元化,業務遍及美國新英格蘭、東南部、中南部和中西部地區的10個不同州以及加拿大新斯科舍省。
NON-IFRS MEASURES:
This release contains references to certain measures that do not have a standardized meaning under IFRS as prescribed by the International Accounting Standards Board ("IASB") and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement IFRS measures by providing a further understanding of operations from management's perspective. Accordingly, non-IFRS financial measures should not be considered in isolation or as a substitute for analysis of financial information reported under IFRS. The Company presents non-IFRS financial measures, specifically Adjusted EBITDA (as such term is hereinafter defined), as well as supplementary financial measures such as annualized revenue and annualized adjusted EBITDA. The Company believes these non-IFRS financial measures are frequently used by lenders, securities analysts, investors and other interested parties as a measure of financial performance, and it is therefore helpful to provide supplemental measures of operating performance and thus highlight trends that may not otherwise be apparent when relying solely on IFRS financial measures.
非國際財務報告準則指標:
本新聞稿提及的某些指標在國際會計準則理事會(“IASB”)規定的國際財務報告準則下沒有標準化含義,因此不太可能與其他公司提出的類似指標相提並論。相反,這些指標是作爲補充信息提供的,通過從管理層的角度進一步了解運營情況,對國際財務報告準則的衡量標準進行了補充。因此,不應孤立地考慮非《國際財務報告準則》的財務指標,也不應將其作爲根據《國際財務報告準則》報告的財務信息分析的替代品。公司提供非國際財務報告準則財務指標,特別是調整後的息稅折舊攤銷前利潤(定義見下文),以及補充財務指標,例如年化收入和年化調整後息稅折舊攤銷前利潤。該公司認爲,貸款人、證券分析師、投資者和其他利益相關方經常使用這些非國際財務報告準則財務指標來衡量財務業績,因此,提供經營業績的補充衡量標準,從而突出僅依賴國際財務報告準則財務指標時可能不明顯的趨勢,是很有幫助的。
Adjusted Earnings before interest, taxes, amortization and depreciation ("Adjusted EBITDA"), is calculated as income from operating activities plus amortization and depreciation and stock-based compensation expense. The most directly comparable IFRS measure is income from operating activities.
調整後的扣除利息、稅項、攤銷和折舊前的收益(“調整後的息稅折舊攤銷前利潤”)按經營活動收入加上攤銷和折舊以及股票薪酬支出計算。最直接可比的《國際財務報告準則》衡量標準是經營活動收入。
FORWARD LOOKING INFORMATION:
Certain information in this press release may contain forward-looking statements, such as statements regarding future expansions and cost savings and plans regarding future acquisitions and business growth, including anticipated annualized revenue or annualized recurring revenue run rate growth and anticipated consolidated Adjusted EBITDA margins. This information is based on current expectations and assumptions, including assumptions described elsewhere in this release and those concerning general economic and market conditions, availability of working capital necessary for conducting Nova Leap's operations, availability of desirable acquisition targets and financing to fund such acquisitions, and Nova Leap's ability to integrate its acquired businesses and maintain previously achieved service hour and revenue levels, that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Risks that could cause results to differ from those stated in the forward-looking statements in this release include the impact of the COVID-19 pandemic or any recurrence, including staff and supply shortages, regulatory changes affecting the home care industry or government programs utilized by the Company, other unexpected increases in operating costs and competition from other service providers. All forward-looking statements, including any financial outlook or future-oriented financial information, contained in this press release are made as of the date of this release and included for the purpose of providing information about management's current expectations and plans relating to the future, and these statements may not be appropriate for other purposes. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in the Company's filings with the Canadian securities regulators, which filings are available at .
前瞻性信息:
本新聞稿中的某些信息可能包含前瞻性陳述,例如有關未來擴張和成本節約的陳述,以及有關未來收購和業務增長的計劃,包括預期的年化收入或年化經常性收入增長率以及預期的合併調整後息稅折舊攤銷前利潤率。這些信息基於當前的預期和假設,包括本新聞稿其他地方描述的假設以及與總體經濟和市場狀況、開展Nova Leap運營所需的營運資金的可用性、理想收購目標和融資的可用性,以及Nova Leap整合其收購業務和維持先前實現的服務時間和收入水平的能力有關的假設,這些假設都存在難以預測的重大風險和不確定性。實際結果可能與任何前瞻性陳述中建議的結果存在重大差異。可能導致結果與本新聞稿前瞻性陳述中陳述的結果不同的風險包括 COVID-19 疫情或任何復發的影響,包括人員和供應短缺、影響家庭護理行業或公司使用的政府計劃的監管變化、運營成本的其他意外增加以及來自其他服務提供商的競爭。本新聞稿中包含的所有前瞻性陳述,包括任何財務展望或面向未來的財務信息,均自本新聞稿發佈之日起作出,其包含的目的是提供有關管理層當前預期和未來計劃的信息,這些陳述可能不適用於其他目的。除非適用於公司的證券法有要求,否則公司沒有義務更新前瞻性陳述,也沒有義務更新實際業績可能與前瞻性陳述中反映的結果不同的原因。識別風險和不確定性的其他信息包含在公司向加拿大證券監管機構提交的文件中,這些文件可在以下網址查閱 。
CAUTIONARY STATEMENT:
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
警示聲明:
多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
CONTACT: For further information: Chris Dobbin, CPA, CA Director, President and CEO Nova Leap Health Corp. T: 902 401 9480 E: cdobbin@novaleaphealth.com
聯繫人:欲了解更多信息:Chris Dobbin,註冊會計師、加州董事、總裁兼首席執行官 Nova Leap Health Corp. T: 902 401 9480 E: cdobbin@novaleaphealth.com
譯文內容由第三人軟體翻譯。